Current Report Filing (8-k)
August 15 2022 - 4:19PM
Edgar (US Regulatory)
0001649989
false
0001649989
2022-08-11
2022-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 2054
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): August 11, 2022
Outlook Therapeutics,
Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-37759 |
38-3982704 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
485 Route 1 South
Building F, Suite 320
Iselin, New Jersey |
08830 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code:
(609) 619-3990
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities pursuant to Section 12 (b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which
Registered |
Common Stock |
|
OTLK |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2022 (“Effective Date”), upon the recommendation
of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”)
of Outlook Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) members, and effective
upon the Effective Date, appointed Dr. Julia A. Haller to fill the newly created vacancy, with Dr. Haller to serve on the Board as a Class
II director until the Company’s 2024 annual meeting of stockholders, until her successor has been duly elected and qualified, or
until her earlier death, resignation or removal. Based upon the further recommendation of its Nominating Committee, the Board, effective
upon the Effective Date, appointed (i) Dr. Haller to serve as a member of the Nominating and Corporate Governance Committee, replacing
Randy Thurman. Randy Thurman will continue to serve as a member of the Board and on any other respective committees of the Board to which
he is appointed, for his respective terms. Dr. Haller was not selected by the Board to serve as a director pursuant to any arrangement
or understanding with any person.
Dr. Haller will receive compensation as non-employee directors in accordance
with the Company’s non-employee director compensation policy that took effect on October 1, 2019 and as amended October 1, 2020,
as described in the Company’s definitive proxy statement for the 2022 Annual Meeting of Stockholders, filed with the Securities
and Exchange Commission on January 27, 2022. Pursuant to the automatic grant program under such policy, Dr. Haller was granted an option
to purchase 25,000 shares of the Company’s common stock under the Company’s 2015 Equity Incentive Plan, which vests annually
over three-years, subject to Dr. Haller’s continuous service through the applicable vesting dates, and acceleration in the event
of a change of control as defined in the plan. Such option grants have an exercise price of $1.15 per share (the closing sales price of
the Company’s common stock on August 11, 2022 as reported on The Nasdaq Capital Market) and a term of 10 years, subject to earlier
termination for cessation of continuous service.
In connection with the aforementioned appointments to the Board, the
Company entered into its standard indemnification agreement, which form indemnity agreement is filed as Exhibit 10.12 to the Company’s
registration statement on Form S-1 (File No. 333-209011) filed with the SEC on January 15, 2016 with Dr. Haller, which requires the Company,
under the circumstances and to the extent provided for therein, to indemnify the indemnitee to the fullest extent permitted by applicable
law against certain expenses and other amounts incurred by her as a result of either of her being made a party to certain actions, suits,
investigations and other proceedings.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Outlook Therapeutics, Inc. |
|
|
Date: August 15, 2022 |
By: |
/s/ Lawrence A. Kenyon |
|
|
Lawrence A. Kenyon |
|
|
Chief Financial Officer |
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024